Andelyn Biosciences Collaborates with Grace Science to Further Develop GS-100

Partnership between Grace Science and Andelyn Biosciences: Expediting GS-100, a Groundbreaking Gene Therapy for NGLY1 Deficiency

Grace Science LLC, a leading biotechnology company, has partnered with Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), to develop GS-100, a suspension process AAV NGLY1 gene therapy aimed at treating NGLY1 Deficiency.

NGLY1 Deficiency is a debilitating condition that affects patients with life-long symptoms. The collaboration between Grace Science and Andelyn Biosciences seeks to increase program efficiency, support ongoing clinical trials, and expedite the availability of this crucial therapy to patients in need.

GS-100 is a recombinant AAV9 vector containing the full-length human NGLY1 gene. In 2021, it received orphan drug designation (ODD) from the FDA and the European Medicine Agency (EMA). The FDA also granted Rare Pediatric Disease Designation to GS-100 in 2021, potentially leading to a Priority Review Voucher upon approval for marketing and a Fast-Track designation in 2023. Grace Science successfully administered the first dose of GS-100 to an NGLY1 Deficiency patient in February of this year and plans to treat a second patient in May 2024.

Through this partnership, Grace Science will leverage Andelyn’s expertise in AAV processes and capabilities in late-stage manufacturing and commercial readiness to expedite its manufacturing timelines, offering hope to patients with NGLY1 Deficiency.

Matt Wilsey, CEO and Co-Founder of Grace Science, expressed his excitement about the partnership with Andelyn Biosciences. He noted that Andelyn’s expertise and experience in AAV gene therapy manufacturing would ensure that NGLY1 patients receive safe, high-quality drug products for clinical trials and beyond.

Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, highlighted their shared values of strong collaboration, customer-centric focus, and a quality-first mindset. These values instill confidence and hope in the success of the GS-100 program.

Leave a Reply

Study finds health risks due to unsafe drinking water in U.S. prisons Previous post Half of US Prisons at Risk for PFAS Pollution, Highlighting Environmental Justice Issues and Health Disparities in the Justice System
The TikTok Revolution: How the Social Network’s Success Sparked a Dispute Between China and the United States | TECHNOLOGY Next post TikTok’s Personalized Approach: How the Social Media Platform Engages and Monetizes its 1.56 Billion Users